South Africa and France Lead the Way in Public and Private Sector Gender Diversity, Latest Research by Kearney Reveals
2.3.2021 17:00:00 EET | Business Wire | Press release
The latest ‘Gender Equality Report’ from Kearney has revealed progress in the representation of women in both public and private sectors, but the figures still don’t show parity.
Ahead of International Women’s Day, the analysis provides insight into the progress of gender diversity in private and public sectors across nine countries – the United States, United Kingdom, Australia, India, France, Spain, Germany, South Africa and Singapore.
The annual report revealed that France was number one for representation in the private sector with women comprising nearly 44% (43.8%) of board members on average, however only 2% of these women held top board positions. The UK (36%) and Australia (34%) also scored highly for representation of women on boards. The average for board level representation of women is 29.9% - not even one in three.
|
% Female board level representation by country |
|
|
France |
43.8% |
|
UK |
36.0% |
|
Australia |
34.0% |
|
Germany |
32.5% |
|
Spain |
29.8% |
|
US |
29.8% |
|
South Africa |
28.5% |
|
Singapore |
17.3% |
|
India |
17.0% |
The public sector – meaning members of Parliament or equivalent – is faring slightly better. The average across the countries surveyed is 33.2% - a marginal difference compared to the private sector – but two thirds (6 out of 9) countries showed more promising gender parity in their governments compared to on their boards. South Africa led the way in the public sector with 44% of its MPs being women – a huge step up from its 28.5% parity at board level – though France is the most gender-diverse nation when taking an average across both its parliament and the boards of its largest companies. The average across both sectors is 32% female representation, whereas France is a leader with 40.4% parity overall.
|
% Female parliament representation by country |
|
|
South Africa |
44.0% |
|
Spain |
42.0% |
|
Australia |
38.0% |
|
France |
37.0% |
|
UK |
34.0% |
|
Germany |
33.0% |
|
Singapore |
30.0% |
|
US |
27.0% |
|
India |
14.0% |
This year’s annual report demonstrates modest progress compared with 2020. Representation of women in the private sector has increased marginally in the United States (1.2%), United Kingdom (3%) and Australia (0.6%), as well as in the parliaments in Australia (1%) and the United States (3.5%), which had a record year for women elected. India remains the least gender diverse country studied with representation of women under 20% across both public (14%) and private sectors (17%).
Beth Sehgal, global director of diversity, equity, and inclusion at Kearney, comments:
“It’s positive to see businesses and governments move towards equal representation as women hold an increasing number of high-ranking positions. However, progress has been slow, and the gender leadership gap endures. France is leading the way for private sector representation and South Africa ranks number one for public sector diversity, and the progress of these two countries should provide benchmarks as we work towards achieving gender parity worldwide.
“Diversity, Equity and Inclusion initiatives will need to be prioritized, particularly in countries lagging behind. Diversity has regularly been linked to high-performance with a variety of perspectives encouraging fresh ideas and preventing the dreaded group think. As the economy rebuilds from the aftermath of coronavirus, it will be crucial women are fairly represented in both public and private sector roles to help assist in its recovery and to avoid a regression on gender equality or “she-cession”.”
About Kearney
As a global consulting partnership in more than 40 countries, our people make us who we are. We’re individuals who take as much joy from those we work with as the work itself. Driven to be the difference between a big idea and making it happen, we help our clients break through. Learn more at Kearney.com.
About the research
Kearney‘s Gender Equality Report 2021 was based on research using publicly available data across nine countries – UK, US, France, Germany, Spain, Australia, India and Singapore – regarding the representation of women at board level and in their respective parliaments. Board information was gathered using the support of Factset.
Read the report: https://www.kearney.com/web/international-womens-day/article/?/a/the-equality-dilemma
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005622/en/
Contact information
Press contact
Sophie Mellish
Rostrum – PR consultants to Kearney
s.mellish@rostrum.agency
+44 7789 712 597
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
